Yonsei University · 医学
Professor Do Young Kim's research lab specializes in liver disease research with a focus on hepatocellular carcinoma (HCC) and liver fibrosis. The lab investigates noninvasive diagnostic methods such as liver stiffness measurement (LSM) and tumor markers like PIVKA-II and AFP to improve early detection and risk stratification. It also explores the impact of antiviral therapy and imaging response—particularly lipiodol uptake after transarterial chemoembolization—on clinical outcomes in HCC patients. The lab aims to develop personalized surveillance and treatment strategies based on biomarkers and imaging features.
Figures are computed from collected data and may differ slightly.
LSPS is a reliable, noninvasive method for detection of HEVs. Patients with LSPS<3.5 may avoid endoscopy safely, whereas those with LSPS>5.5 should be considered for appropriate prophylactic treatments.
Hepatocellular carcinoma (HCC) is one of the most frequently occurring malignancies and has a high mortality rate. The incidence of HCC differs greatly according to the geographic area. East and Southeast Asia, as well as middle and West Africas have the highest prevalence of HCC. The risk factors for developing HCC are well known and include cirrhosis, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcohol consumption, smoking, diabetes, and nonalcoholic steatohepatitis.
LS values at CVR are useful for predicting forthcoming LRE development. Thus, in the era of potent antiviral therapy, tailored surveillance strategies might be established based upon LS values at CVR.
Approximately 80% of hepatocellular carcinoma (HCC) cases arise in sub-Saharan Africa and Eastern Asia, following a similarly high prevalence of chronic hepatitis B virus (HBV) carriers in these regions. The etiology and epidemiology of HCC have recently changed worldwide. Although HBV infection is the main contributor to HCC development, a slow but continuous decline in HBV infection rates has been reported since 1990. Owing to the widespread use of direct-acting antivirals, the incidence of he
Our data suggest that PIVKA-II is a useful tumor marker for HCC, complementary to AFP. Serial measurements of both markers after resection might be helpful for early diagnosis of tumor recurrence.
Initial compact lipiodol uptake after transarterial chemoembolisation is associated with improved survival in patients with unresectable hepatocellular carcinoma. Accordingly, initial complete lipiodolisation should be considered a relevant therapeutic target.
Diagnostic accuracy improved upon combining the AFP, PIVKA-II, and AFP-L3 tumor markers compared to each marker alone in detecting HCC and early HCC in cirrhotic patients.
Abstract Background & Aims The aim of this study was to reveal nationwide seroprevalence of HCV infection in South Korea by a large‐scale survey. Methods From January to December 2009, a total of 291 314 adults underwent health check‐up in 29 centres nationwide. The data concerning anti‐ HCV antibody and biochemical tests were obtained from all participants. Among subjects with positive anti‐ HCV , such data as HCV RNA , genotypes and treatment detail were additionally analysed. Results Usin
Open papers in the app to read, cite, and organize with AI.
